CSL Limited (OTCMKTS:CSLLY) Short Interest Update

CSL Limited (OTCMKTS:CSLLY) was the target of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 600 shares, a decline of 62.5% from the November 15th total of 1,600 shares. Based on an average daily trading volume, of 307,600 shares, the short-interest ratio is presently 0.0 days.

CSL Trading Down 0.5 %

Shares of CSL stock traded down $0.48 during trading hours on Wednesday, hitting $89.44. The company’s stock had a trading volume of 24,925 shares, compared to its average volume of 35,915. The company has a quick ratio of 0.97, a current ratio of 2.18 and a debt-to-equity ratio of 0.58. The stock has a 50 day moving average of $94.55 and a 200 day moving average of $98.04. CSL has a 12 month low of $85.70 and a 12 month high of $109.00.

Wall Street Analysts Forecast Growth

Separately, Macquarie raised CSL to a “strong-buy” rating in a research note on Tuesday, August 13th.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.